Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients

Aims To report the cardiovascular (CV) safety profile and heart failure (HF) risk of vildagliptin from a large pool of studies, including trials in high‐risk patients with type 2 diabetes mellitus (T2DM), such as those with congestive HF and/or moderate/severe renal impairment. Methods We conducted...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2015-11, Vol.17 (11), p.1085-1092
Hauptverfasser:	McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., Kothny, W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - adverse effects Adamantane - analogs & derivatives Aged Aged, 80 and over antidiabetic drug cardiovascular disease Cardiovascular Diseases - chemically induced Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy dipeptidyl peptidase-4 inhibitor Dipeptidyl-Peptidase IV Inhibitors - adverse effects Female Glycated Hemoglobin A - analysis Heart Failure - chemically induced Humans Hypoglycemic Agents - adverse effects Male meta-analysis Middle Aged Nitriles - adverse effects Pyrrolidines - adverse effects Randomized Controlled Trials as Topic Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!